Detailed Information
Cited 22 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.
- Authors
- Paz-Ares, LG[Paz-Ares, Luis G.]; Ciuleanu, TE[Ciuleanu, Tudor-Eliade]; Lee, JS[Lee, Jong-Seok]; Urban, L[Urban, Laszlo]; Caro, RB[Caro, Reyes Bernabe]; Park, K[Park, Keunchil]; Sakai, H[Sakai, Hiroshi]; Ohe, Y[Ohe, Yuichiro]; Nishio, M[Nishio, Makoto]; Pluzanski, A[Pluzanski, Adam]; Ramalingam, SS[Ramalingam, Suresh S.]; Brahmer, JR[Brahmer, Julie R.]; Borghaei, H[Borghaei, Hossein]; O'Byrne, KJ[O'Byrne, Kenneth John]; Hellmann, MD[Hellmann, Matthew D.]; Memaj, A[Memaj, Arteid]; Bushong, J[Bushong, Judith]; Tran, P[Tran, Phuong]; Reck, M[Reck, Martin]
- Issue Date
- 20-May-2021
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.39, no.15
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 39
- Number
- 15
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.